Exosome diagnostic and therapeutic market size was valued at $224.34 million in 2020, and is projected to reach $2.9 billion by 2030, growing at a CAGR of 29.4%.
Increased usage of exosome therapy’s multifunctional properties for chronic heart failure, Alzheimer’s disease, Parkinson’s disease, and cancer, including breast, liver, prostate, and lung cancer, is a key factor driving the research on exosomes. Aethlon Medical, a healthcare startup, also announced a collaboration with the University of Pittsburgh on a National Institute of Health grant for the treatment of head and neck cancer in August 2020. Exosomes are nano-sized particles that are released in great quantities by cancer cells that contain a tumor’s genetic and protein cargo, fueling cancer growth and suppressing the immune system.
Download Sample PDF at:
https://www.alliedmarketresearch.com/request-sample/1723
Covid-19 scenario-
Rapid spread of Covid-19 heightened the need for molecular diagnosis, thus impacting the global exosome diagnostic and therapeutic market positively.
This trend is pretty likely to continue till the pandemic is completely over.
The diagnostic segment to dominate by 2030-
Based on application, the diagnostic segment accounted for more than two-thirds of the global exosome diagnostic and therapeutic market share in 2020, and is anticipated to rule the roost by 2030. The same segment would also cite the fastest CAGR of 29.5% throughout the forecast period, due to rise in incidence of chronic disease and surge in demand for early diagnosis.
Specific Requirement on COVID-19? Ask to Our Industry Expert: https://www.alliedmarketresearch.com/purchase-enquiry/1723
The instrument segment to maintain the lion’s share-
Based on product, the instrument segment held nearly three-fifths of the global exosome diagnostic and therapeutic market revenue in 2020, and is expected to lead the trail by 2030. This is owing to increase in need for molecular diagnosis and surge in R&D activities for the purpose of diagnosis. The software segment, on the other hand, would manifest the fastest CAGR of 30.2% from 2020 to 2030. This is attributed to advancements in R&D activities in the healthcare sector and increase in number of key manufacturers across the world.
North America garnered the major share in 2020-
Based on region, North America held the major share in 2020, generating nearly two-fifths of the global exosome diagnostic and therapeutic market, due to rise in product launches for exosome therapeutics, surge in the presence of key players, and development of R&D activities in the pharmaceutical and biopharmaceutical sector across the province. Asia-Pacific, however, would grow at the fastest CAGR of 30.3% by 2030. Increase in the prevalence of chronic and infectious disorders, growth in health care expenditures, and surge in demand for molecular diagnosis drive the market growth in the region.
Key players in the industry-
Exosome Diagnostics Inc.
NanoSomix Inc.
Thermo Fisher Scientific Inc.
Malvern Instruments Ltd.
System Biosciences Inc.
NX Pharmagen
Aethlon Medical, Inc.
Sistemic Inc.
About Allied Market Research:
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of ‘Market Research Reports’ and ‘Business Intelligence Solutions.’ AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.